

Please type a plus sign (+) inside this box →

PTO/SB/21 (08-00)

Approved for use through 10/31/02. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE to a collection of information unless it displays a valid OMB control number. Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of info

| TRANSMITTAL | Application Number | 09/894,018 | |
|---|---|---|-------------|
| | Filing Date | June 27, 2001 | |
| FORM | First Named Inventor | Alessandro SETTE et al. | SH |
| | Group Art Unit | 1642 | CEN. |
| (to be used for all correspondence after initial filing) | Examiner Name | To be assigned | <u> </u> |
| Total Number Of Pages in This Submission | Attorney Docket No. | 399632003300 | Ī |
| ENCLOS | URES (check all that | apply) | 4 /2 |
| | signment Papers an Application) | After Allowance Communication to | _ |
| | wing(s) | Appeal Communication to Board o Appeals and Interferences | f |
| Amendment / Reply | ensing-related Papers | Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) | |
| After Final Peti | ition | Proprietary Information | |
| | ition to Convert to a visional Application | Status Letter | |
| | ver of Attorney, Revocation ange of Correspondence Add | Other Enclosure(s) (please identify below): Return postcard | |
| - | minal Disclaimer | | |
| Express Abandonment Request Req | quest for Refund | | |
| Information Disclosure Statement; PTO form 1449; and 51 references. | , Number of CD(s) | | |
| Certified Copy of Priority Document(s) Remarks | | | |
| Response to Missing Parts/ Incomplete Application | _ | | |
| Response to Missing Parts under 37 CFR 1.52 or 1.53 | | | |
| | | | |
| SIGNATURE OF A | APPLICANT, ATTORN | EY OR AGENT | |
| Firm Bruce Grant, Registration No. 47,60 | 08 | | - |
| or Morrison & Foerster Individual Name 3811 Valley Centre Drive, Ste 500 | | | |
| Sap Diego, CA 92130 | | | |
| Signature | | | |
| Date March 6, 2002 | | | |
| | 77 | | |
| / CERTIFICATE O | OF MAILING BY "FIRST CL | ASS MAIL" | \neg |
| I hereby certify that this correspondence is being deposited to: Assistant Commissioner for Patents, Washington, D.C. | 20231, on March 6, 2002 | tal Service as first class mail in an envelope addres | sed |
| Burden Hours Statement: This form is estimated to take 0.2 hours to complete | Susan B. Lynch | | |

Burden Hours Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to

Assistant Commissioner for Patents, Washington, D.C. 20231, on March \$\mathbb{b}, 2002.

Susan B. Lynch

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Alessandro SETTE et al.

Serial No.:

09/894,018

Filing Date:

June 27, 2001

For:

METHOD AND SYSTEM FOR

OPTIMIZING MINIGENES AND PEPTIDES ENCODED THEREBY Examiner: To be assigned

Group Art Unit: 1642

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97

Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the documents are also submitted herewith. The Examiner is requested to make these documents of record.

This application may be relevant to U.S.S.N. 09/189,702 filed 11/10/98, which is a CIP of U.S.S.N 08/205,713 filed 3/4/94, which is a CIP of 08/159,184 filed 11/29/93 and now abandoned, which is a CIP of 08/073,205 filed 6/4/93 and now abandoned, which is a CIP of 08/027,146 filed 3/5/93 and now abandoned. The present application is also related to U.S.S.N. 09/226,775, which is a CIP of U.S.S.N. 08/815,396, which claims the benefit of U.S.S.N. 60/013,113, now abandoned. Furthermore, the present application is related to U.S.S.N. 09/017,735, which is a CIP of abandoned U.S.S.N. 08/589,108; U.S.S.N. 08/753,622, U.S.S.N. 08/822,382, abandoned U.S.S.N. 60/013,980, U.S.S.N. 08/454,033, U.S.S.N. 09/116,424, and U.S.S.N. 08/349,177. The present application is also related to U.S.S.N. 09/017,524, U.S.S.N. 08/821,739, abandoned U.S.S.N. 60/013,833, U.S.S.N. 08/758,409, U.S.S.N. 08/589,107, U.S.S.N. 08/451,913, U.S.S.N. 08/186,266, U.S.S.N. 09/116,061, and U.S.S.N. 08/347,610, which is a CIP of U.S.S.N. 08/159,339, which is a CIP of abandoned U.S.S.N. 08/103,396, which is a CIP of abandoned U.S.S.N. 08/027,746, which is a CIP of abandoned U.S.S.N. 07/926,666. The present application may also be relevant to U.S.S.N. 09/017,743, U.S.S.N. 08/753,615; U.S.S.N. 08/590,298, U.S.S.N. 09/115,400, and U.S.S.N. 08/452,843, which is a CIP of U.S.S.N. 08/344,824, which is a CIP of abandoned U.S.S.N. 08/278,634. The present application may also be related to provisional U.S.S.N. 60/087,192 and U.S.S.N. 09/009,953, which is a CIP of abandoned U.S.S.N. 60/036,713 and abandoned U.S.S.N. 60/037,432. In addition, the present application may be relevant to U.S.S.N. 09/098,584, and U.S.S.N. 09/239,043. The present application may also be relevant to co-pending U.S.S.N. 09/583,200 filed 5/30/00, U.S.S.N. 09/260,714 filed 3/1/99, and U.S. Provisional Application "Heteroclitic Analogs And Related Methods", Attorney Docket Number 018623-015810US filed 10/6/00.

This Information Disclosure Statement is submitted:

| | With the application; accordingly, no fee or separate requirements are required. |
|-------------|---|
| \boxtimes | Within three months of the application filing date or before mailing of a first Office |
| | Action on the merits; accordingly, no fee or separate requirements are required. |
| | After receipt of a first Office Action on the merits but before mailing of a final Office |
| | Action or Notice of Allowance |

| | A fee is required. A check in the amount of * is enclosed. |
|---------|--|
| | A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached |
| | to this submission in duplicate. |
| | A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly; no fee |
| | is believed to be due. |
| After | mailing of a final Office Action or Notice of Allowance, but before payment of the |
| issue i | fee. |
| | A Certification under 37 C.F.R. § 1.97(e) is provided below and a check in the |
| | amount of * is enclosed. |
| | A Certification under 37 C.F.R. § 1.97(e) is provided below and a Fee Transmittal |
| | form (PTO/SR/17 is attached to this submission in dunlicate |

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 399632003300. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: March 6, 2002

Respectfully submitted,

By

Bruce D. Grant

Registration No. (47,608)

Morrison & Foerster LLP 3811 Valley Centre Drive

Suite \$00

San Diego, California 92130-2332

Telephone: (858) 720-7962 Facsimile: (858) 720-5125

| Form P1O-1449 | Docket Nulliber 399032003300 | Application Num |
|---------------------------------|------------------------------|-----------------|
| INFORMATION DISCLOSURE CITATION | Applicant | |
| IN AN APPLICATION | Alessandro | SETTE et al. |
| /01FE | | |

Applicant

Alessandro SETTE et al.

Filing Date June 27, 2001

Mailing Date March 6, 2002

Application Number 09/894,018

Group Art Unit 1642

MAR 1 2 2002

U.S. PATENT DOCUMENTS

| Examiner Initials | Ref. No. | Date | Document No. | Name | Class | Subclass | Filing Date If Appropriate |
|----------------------|-------------|------------|--------------|---------------|-------|----------|----------------------------|
| | 1. | 05/27/1997 | 5,633,234 | August et al. | 514 | 44 | |
| | 2. | 04/07/1998 | 5,736,142 | Sette et al. | 424 | 185.1 | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials | Ref. No. | Date | Document No. | Country | Class | Subclass | Trans YES | lation NO |
|-------------------|-------------|------------|--------------|---------|-------|----------|--------------|--------------|
| | 3. | 02/06/1997 | WO 97/03778 | wo | | | X | |
| | 4. | 03/04/1999 | WO 99/10646 | WO | | | | X |
| | 5. | 04/06/2000 | WO 00/19774 | wo | | | | X |
| | 6. | 05/18/2000 | WO 00/27766 | wo | | | | X |

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

| Examiner Initials | Ref. No. | Title |
|----------------------|-------------|---|
| | 7. | Anton et al. (1997). J Immunol 158(6):2535-42. |
| | 8. | Arndt et al. (1997). Immunol Res 16(3):261-72. |
| | 9. | Bergmann et al. (1994). J Virol. 68(8):5306-10. |
| | 10. | Bergmann et al. (1996). J Immunol 157(8):3242-9. |
| | 12. | Bertoni et al. (1997). J Clin Invest. 100(3):503-13. |
| | 13. | Blum et al. (1997). Crit Rev Immunol 17(5-6):411-7. |
| | 14. | Chapman, H.A. (1998). Curr Opin Immunol 10(1):93-102. |
| | 15. | Chimini et al. (1989). J Exp Med 169(1):297-302. |
| | 16. | Copier et al. (1996). J. Immunol. 157:1017-1027. |
| | 17. | Couillin et al. (1994). J Exp Med 180(3):1129-34. |
| | 18. | Del Val et al. (1991). Cell 66(6):1145-53. |
| | 19. | Diminsky et al. (1997). Vaccine 15:637-647. |
| | 20. | Doolan et al. (1997). Immunity 7(1):97-112. |

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

| Form PTO-1449 | | Docket Number 399632003300 | Application Number 09/ | 894,018 | |
|-------------------|--|----------------------------|-----------------------------|-----------|-------------|
| -PMFORMAT | TION DISCLOSURE CITATION | Applicant | | | |
| IN AN APPLICATION | | Alessandro SETTE et al. | | | |
| MAR , a SO | | Filing Date June 27, 2001 | · Group Art Unit 1642 | 운 | |
| MAR 1 2 2002 | | Mailing Date March 6, 2002 | | CENT T | MAR |
| A DEMARK OFF | 4 | | | 굨 | |
| 21. | Gileadi et al. (1999). Eur J Immunol 2 | | | | 9 |
| 22. | Hahn et al. (1991). J Exp Med 174(3): | | | <u> </u> | 2002 |
| 23. | Hahn et al. (1992). J Exp Med 176(5): | | | 1500/2900 | |
| 24. | Hanke et al (1998). J Gen Virol 79(Pt | | | | |
| 25. | Hunt et al. (1992). Science 256(5065): | | | | |
| 26. | Ishioka et al. (1999). J Immunol 162(7 | | | | |
| 27. | Iwasaki et al. (1999). Vaccine 17(15-1 | | | | |
| 28. | LeBorgne et al. (1998). Virology 240: | | | | |
| 29. | Lippolis et al. (1995). J Virol 69(5):31 | 34-46. | | | |
| 30. | Livingston et al. (1997). J Immunol 15 | 59(3):1383-92. | | | |
| 31. | Mateo et al. (1999). J Immunol 163(7) | :4058-63. | | | |
| 32. | Moudgil et al. (1997). J Immunol 1596 | (6):2574-9. | | | |
| 33. | Nakagawa et al. (1999). Immunity 10(| 2):207-17. | | | |
| 34. | Niedermann et al (1995). Immunity 2(| 3):289-99. | | | |
| 35. | Ogg G.S. et al. (1998). Curr Opin Imn | nunol 10(4):393-6. | | | |
| 36. | Paz et al. (1999). Immunity 11(2):241- | -51. | | | |
| 37. | Perkins et al (1991). J Immunol 146(7 |):2137-44. | | | |
| 38. | Rammensee et al. (1995). Immunogen | etics 41:178-228. | | | |
| 39. | Restifo et al. (1995). J Immunol 154(9 |):4414-22. | | | |
| 40. | Sette et al. (1989). J. Immunol. 143:12 | 268-73. | | | |
| 41. | Shastri et al. (1995). J Immunol 155(9 |):4339-46. | | | |
| 42. | Theobald et al. (1998). J Exp Med 188 | 3(6):1017-28. | | | |
| 43. | Thomson et al. (1998). J Immunol 160 | | | | |
| 44. | Thomson et al. (1998). J Virol 72(3):2 | 246-52. | | | |
| 45. | Thomson et al. (1995). Proc Natl Acad | d Sci USA 92(13):5845-9. | | | |
| 46. | Threlkeld et al. (1997). J. Immunol. 15 | 59(4):1648-57. | | | |
| 47. | Tussey et al. (1995). Immunity 3(1):65 | <i>5-</i> 77. | | | |
| 48. | Wang et al. (1992). Cell Immunol 143 | (2):284-97. | | | |
| 49. | Wherry et al. (1999). J Immunol 163(7) | 7):3735-45. | | | |
| 50. | Woodberry et al. (1999). J Virol 73(7) | :5320-5. | | | |
| EXAMINER: | | DATE CONSIDERED: | | * | |
| | tial if citation considered, whether or not the citati not considered. Include a copy of this form with r | | a line through the citation | if not in | 1 |

| Form PTO-1449 | Docket Number 399632003300 | Application Number 09 | /894,018 | |
|---|----------------------------|-----------------------|------------------|----------|
| INFORMATION DISCLOSURE CITATION IN AN APPLICATION | Applicant Alessan | dro SETTE et al. | | |
| পু | Filing Date June 27, 2001 | Group Art Unit 1642 | 유 | |
| 1 2 2002 \$ | Mailing Date March 6, 2002 | | CE | MAR |
| | | | 二 計 | ۳ |
| ADEMARY 51. Yewdell et al. (1999). Annu Rev Imm | nunol 17:51-88. | | 하 | <u>و</u> |
| | | | CENTER 1500/2900 | 1002 |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| EXAMINER: | DATE CONSIDERED: | | | |